Iktos Raises € 15.5m Series A Round To Expand Its Artificial Intelligence-based Drug Discovery Technologies And Solutions

Iktos, a company specializing in artificial intelligence for new drug discovery, announced the closing of a € 15.5m Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable the company to further develop its AI and drug discovery capabilities and expand its existing SaaS software offering, in addition to launching Iktos Robotics; a unique, end-to-end, drug discovery platform which combines artificial intelligence and automation of chemical synthesis.